Supplementary Table S6 from Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer
Year: 2025
Type: supplementary-materials
Abstract: Supplementary Table S6 shows Treatment Related Adverse Events of Special Interest in patients treated with rebastinib (n = 27).
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4406541122